Loading...
Incyte Corporation
INCY•NASDAQ
Healthcare
Biotechnology
$70.20
$-0.29(-0.41%)
Incyte Corporation (INCY) Financial Performance & Income Statement Overview
Review Incyte Corporation’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
14.76%
↑ 14.76%
Operating Income Growth
-90.11%
↓ 90.11%
Net Income Growth
-94.54%
↓ 94.54%
Operating Cash Flow Growth
-32.46%
↓ 32.46%
Operating Margin
3.98%
↑ 3.98%
Gross Margin
92.28%
↑ 92.28%
Net Profit Margin
0.48%
↑ 0.48%
ROE
0.64%
↑ 0.64%
ROIC
4.36%
↑ 4.36%
Incyte Corporation (INCY) Income Statement & Financial Overview
Review Incyte Corporation's (INCY) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.18B | $1.14B | $1.04B | $880.89M |
| Cost of Revenue | $88.50M | $86.00M | $92.98M | $61.00M |
| Gross Profit | $1.09B | $1.05B | $950.78M | $819.89M |
| Gross Profit Ratio | $0.92 | $0.92 | $0.91 | $0.93 |
| R&D Expenses | $466.03M | $573.17M | $1.14B | $429.26M |
| SG&A Expenses | $326.80M | $309.20M | $289.63M | $300.30M |
| Operating Expenses | $788.68M | $905.79M | $1.43B | $728.53M |
| Total Costs & Expenses | $877.18M | $991.79M | $1.52B | $789.53M |
| Interest Income | $10.002M | $24.20M | $49.77M | $44.74M |
| Interest Expense | $419000.00 | $774000.00 | $657000.00 | $430000.00 |
| Depreciation & Amortization | $22.73M | $22.52M | $22.05M | $21.95M |
| EBITDA | $336.88M | $179.82M | -$367.07M | $114.14M |
| EBITDA Ratio | $0.29 | $0.16 | -$0.35 | $0.13 |
| Operating Income | $301.51M | $146.09M | -$477.24M | $91.90M |
| Operating Income Ratio | $0.26 | $0.13 | -$0.46 | $0.10 |
| Other Income/Expenses (Net) | $12.21M | $10.44M | $88.35M | $144.26M |
| Income Before Tax | $313.72M | $156.52M | -$389.78M | $236.16M |
| Income Before Tax Ratio | $0.27 | $0.14 | -$0.37 | $0.27 |
| Income Tax Expense | $112.51M | $50.07M | $54.82M | $66.61M |
| Net Income | $201.21M | $106.46M | -$444.60M | $169.55M |
| Net Income Ratio | $0.17 | $0.09 | -$0.43 | $0.19 |
| EPS | $0.97 | $0.55 | -$2.04 | $0.76 |
| Diluted EPS | $0.96 | $0.54 | -$2.04 | $0.75 |
| Weighted Avg Shares Outstanding | $207.11M | $192.63M | $218.18M | $224.48M |
| Weighted Avg Shares Outstanding (Diluted) | $210.53M | $195.84M | $218.18M | $227.22M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan